Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients

被引:19
作者
Engen, Rachel M. [1 ]
Park, Giulia E. [2 ]
Schumacher, Cooper S. [3 ]
Gimferrer, Idoia [4 ]
Warner, Paul [4 ]
Finn, Laura S. [5 ]
Weiss, Noel S. [6 ]
Smith, Jodi M. [1 ]
机构
[1] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[2] Seattle Childrens Hosp, Div Nephrol, Seattle, WA USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[4] Bloodworks Northwest, Seattle, WA USA
[5] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
关键词
HUMAN LEUKOCYTE ANTIGEN; HLA ANTIBODIES; ALLOGRAFT SURVIVAL; FLOW-CYTOMETRY; HUMORAL THEORY; RISK-FACTOR; REJECTION; IMPACT; C4D; C1Q;
D O I
10.1097/TP.0000000000002310
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The development of de novo donor-specific antibodies (dnDSA) has been associated with rejection and graft loss in kidney transplantation, and DSA screening is now recommended in all kidney transplant recipients. However, the clinical significance of dnDSA detected by screening patients with a stable creatinine remains unclear. Methods. One hundred three patients younger than 18 years receiving a first, kidney alone transplant between December 1, 2007, and December 31, 2013, underwent DSA screening every 3 months for 2 years posttransplant, with additional testing as clinically indicated. No treatment was given for DSAs in the absence of biopsy-proven rejection. Results. Twenty (19%) patients had dnDSA first detected on a screening test, and 13 (13%) patients had dnDSA first detected on a for-cause test. Mean follow-up time posttransplant was 4.4 years. Screening-detected dnDSA was associated with an increased risk of rejection within 3 years, microvascular inflammation, and C4d staining on a 2-year protocol biopsy. In a Cox proportional hazards regression, screening-detected dnDSA was not associated with time to 30% decline in estimated glomerular filtration rate (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.30-2.00; P = 0.598) or graft loss. dnDSA first detected on for-cause testing was associated with a 2.8 times increased risk of decline in graft function (95% CI, 1.08-7.27; P = 0.034) and a 7.34 times increased risk of graft loss (95% CI, 1.37-39.23 P = 0.020) compared with those who did not develop dnDSA. Conclusions. The clinical setting in which dnDSA is first detected impacts the association between dnDSA and graft function. Further research is needed to clarify the role of dnDSA screening in pediatric kidney transplantation.
引用
收藏
页码:2072 / 2079
页数:8
相关论文
共 33 条
[1]   The Impact of De Novo Donor-specific Anti-Human Leukocyte Antigen Antibodies on 5-Year Renal Transplant Outcome [J].
Banasik, M. ;
Boratynska, M. ;
Koscielska-Kasprzak, K. ;
Mazanowska, O. ;
Krajewska, M. ;
Zabinska, M. ;
Bartoszek, D. ;
Myszka, M. ;
Nowakowska, B. ;
Dawiskiba, T. ;
Lepiesza, A. ;
Chudoba, P. ;
Klinger, M. .
TRANSPLANTATION PROCEEDINGS, 2013, 45 (04) :1449-1452
[2]   Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure [J].
Campos, E. F. ;
Tedesco-Silva, H. ;
Machado, P. G. ;
Franco, M. ;
Medina-Pestana, J. O. ;
Gerbase-DeLima, M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (10) :2316-2320
[3]   Donor-specific antibodies after transplantation by flow cytometry - Relative change in fluorescence ratio most sensitive risk factor for graft survival [J].
Christiaans, MHL ;
Overhof-deRoos, R ;
Nieman, F ;
Van Hooff, JP ;
Van den Berg-Loonen, EM .
TRANSPLANTATION, 1998, 65 (03) :427-433
[4]   Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients [J].
Comoli, P. ;
Cioni, M. ;
Tagliamacco, A. ;
Quartuccio, G. ;
Innocente, A. ;
Fontana, I. ;
Trivelli, A. ;
Magnasco, A. ;
Nocco, A. ;
Klersy, C. ;
Rubert, L. ;
Ramondetta, M. ;
Zecca, M. ;
Garibotto, G. ;
Ghiggeri, G. M. ;
Cardillo, M. ;
Nocera, A. ;
Ginevri, F. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (07) :2106-2116
[5]   Inferior Kidney Allograft Outcomes in Patients With De Novo Donor-Specific Antibodies Are Due to Acute Rejection Episodes [J].
Cooper, James E. ;
Gralla, Jane ;
Cagle, Linda ;
Goldberg, Ryan ;
Chan, Laurence ;
Wiseman, Alexander C. .
TRANSPLANTATION, 2011, 91 (10) :1103-1109
[6]   Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations [J].
Dieplinger, Georg ;
Ditt, Vanessa ;
Arns, Wolfgang ;
Huppertz, Andrea ;
Kisner, Tuelay ;
Hellmich, Martin ;
Bauerfeind, Ursula ;
Stippel, Dirk L. .
TRANSPLANT INTERNATIONAL, 2014, 27 (01) :60-68
[7]   Antibody-Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure [J].
Einecke, G. ;
Sis, B. ;
Reeve, J. ;
Mengel, M. ;
Campbell, P. M. ;
Hidalgo, L. G. ;
Kaplan, B. ;
Halloran, P. F. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (11) :2520-2531
[8]   Identifying Specific Causes of Kidney Allograft Loss [J].
El-Zoghby, Z. M. ;
Stegall, M. D. ;
Lager, D. J. ;
Kremers, W. K. ;
Amer, H. ;
Gloor, J. M. ;
Cosio, F. G. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (03) :527-535
[9]   The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes [J].
Freitas, Maria Cecilia S. ;
Rebellato, Lorita M. ;
Ozawa, Miyuki ;
Anh Nguyen ;
Sasaki, Nori ;
Everly, Matthew ;
Briley, Kimberly P. ;
Haisch, Carl E. ;
Bolin, Paul ;
Parker, Karen ;
Kendrick, William T. ;
Kendrick, Scott A. ;
Harland, Robert C. ;
Terasaki, Paul I. .
TRANSPLANTATION, 2013, 95 (09) :1113-1119
[10]   Posttransplant De Novo Donor-Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody-Mediated Rejection [J].
Ginevri, F. ;
Nocera, A. ;
Comoli, P. ;
Innocente, A. ;
Cioni, M. ;
Parodi, A. ;
Fontana, I. ;
Magnasco, A. ;
Nocco, A. ;
Tagliamacco, A. ;
Sementa, A. ;
Ceriolo, P. ;
Ghio, L. ;
Zecca, M. ;
Cardillo, M. ;
Garibotto, G. ;
Ghiggeri, G. M. ;
Poli, F. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (12) :3355-3362